ALXN2060
ALXN2060-TAC-302
Phase 3 small_molecule completed
Quick answer
ALXN2060 for Symptomatic Transthyretin Amyloid Cardiomyopathy is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Symptomatic Transthyretin Amyloid Cardiomyopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed